Salvina Therapeutics AG
PrivateLast Round
Seed
Jul 1, 2024
Total Funding Raised
$4.96M
Company Overview
Salvina Therapeutics AG operates in Healthcare & Life Sciences and is based in Zurich. Its latest recorded funding round was a Seed round in July 2024.
Salvina Therapeutics AG is a biotechnology company that develops novel antibody therapies targeting TNF and TNF superfamily members for the treatment of inflammatory and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Salvina Therapeutics AG Comparables
Compare Salvina Therapeutics AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Navigator Medicines | 82% | |
| SEITO Biologics AG | 81% | |
| Boston Immune Technologies & Therapeutics | 81% |
For institutional investors. Book with your work email.
Salvina Therapeutics AG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jul 1, 2024 | ||||
| Accelerator | Oct 6, 2023 |
For institutional investors. Book with your work email.
Salvina Therapeutics AG Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioMedPartners | Seed |
| JFG Life Sciences Foundation of the University of Basel | Seed |
| BaseLaunch | Accelerator |
| CARMA FUND | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 1, 2024
$4M raised from Novartis and BioMedPartners.
- Oct 6, 2023
$560K raised with BaseLaunch as lead investor.
For institutional investors. Book with your work email.
Salvina Therapeutics AG Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Salvina Therapeutics AG's valuation, stock price, and market status.
Is Salvina Therapeutics AG a public or private company?
Salvina Therapeutics AG is a private company.
What is the current stock price of Salvina Therapeutics AG?
Salvina Therapeutics AG is a private company, so its shares have no public market price. Caplight tracks Salvina Therapeutics AG's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Salvina Therapeutics AG worth (valuation)?
Valuation information for Salvina Therapeutics AG is not publicly available.
Can I buy Salvina Therapeutics AG stock?
Salvina Therapeutics AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Salvina Therapeutics AG's last funding round?
Salvina Therapeutics AG's most recent funding round was Seed on July 1, 2024.
Who are the main investors in Salvina Therapeutics AG?
Key investors in Salvina Therapeutics AG include BaseLaunch.
Will Salvina Therapeutics AG IPO soon?
No public IPO plans have been announced for Salvina Therapeutics AG.
How can I track Salvina Therapeutics AG secondary market activity?
Caplight tracks bids, offers, and trades in Salvina Therapeutics AG's shares on secondary markets.